<DOC>
	<DOCNO>NCT01593332</DOCNO>
	<brief_summary>In project investigator decide evaluate efficacy safety half dose mabthera ( mean 500 mg infusion two week apart ) conventional drug resistant case rheumatoid arthritis . The investigator choose drug use anti-TNF drug limit investigator refractory patient first line drug cost .</brief_summary>
	<brief_title>Low Dose Rituximab First Line Biologic Therapy Treatment DMARD Resistant Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1987 ACR criterion classification RA Positive rheumatoid factor ( RF ) Active RA despite therapy conventional least 3 month evidence DAS 28 &gt; 3/2 Patients active , resistant RA n't receive anti TNF agent . Patient hypogammaglobulinemia Patient congestive heart failure ( classIV ) Active current bacterial , viral , fungal , myocardial infection Chronic hepatitis B hepatitis C carrier History severe allergic reaction human , humanize murine monoclonal antibody History malignancy Pregnant woman lactate mother 8 ) Patients Chronic renal failure hepatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Biologics</keyword>
	<keyword>Anti-tumour necrosis factor</keyword>
	<keyword>Disease-modifying anti-rheumatic drug</keyword>
	<keyword>DAS28</keyword>
	<keyword>European League Against Rheumatism response</keyword>
</DOC>